Skip to main content

stock

URGN · UroGen Pharma Ltd.

What UroGen Pharma Ltd. reports to the SEC, read from its filings.

Open in the app

Price

The live URGN price and today's change.

Sign in to see this

Chart

Thirty days of daily bars, with signal levels drawn on them.

Sign in to see this

Signals

The latest signal group Nakagai's scanner recorded on URGN.

Sign in to see this

Options positioning

Gamma exposure levels from the options market.

Sign in to see this

Technicals

Trend, momentum and volatility gauges per timeframe.

Sign in to see this

What it is

Industry
Pharmaceutical Preparations (SIC 2834)
Filer (SEC EDGAR)
EDGAR filing index
Shares outstanding
48,880,564 as of 2026-07-28 (XBRL frame CY2026Q2I)

Key stats

Valuation

P/E
Locked
P/S
Locked
P/B
Locked
Enterprise value
Locked
EV/EBIT
Locked
FCF yield
Locked

Margins

Gross
90.8%
Operating
-35.3%
Net
-51.7%

Returns

ROE
—
ROA
-38.7%

Health

Current ratio
3.8x
Debt/equity
—

Deep value

NCAV
-$149.56M
NCAV per share
-$3.06
Price/NCAV
Locked
NNWC
-$226.99M
NNWC per share
-$4.64
Price/NNWC
Locked

Valuation and the price multiples are built on the live price. Trailing twelve months to 2026-06-30; balance sheet at 2026-06-30.

Sign in to see this

Debt is long-term debt and its current portion. Commercial paper and short-term borrowings are not counted.

Results

Period endRevenueGross profitOperating incomeNet incomeFiling
2026-06-30$72.46M$65.88M$111,000-$14.35M
10-Q filed 2026-08-05
2026-03-31$50.96M$46.82M-$20.26M-$23.57M
10-Q filed 2026-05-06
2025-12-31$37.84M$34.55M-$19.11M-$26.36M
DEF 14A filed 2026-04-30
Derived: the full year minus the first three quarters, not a figure this filer reported as a quarter.
Assembled from more than one filing; the filing above is only the newest of them.
2025-09-30$27.48M$24.20M-$27.39M-$33.35M
10-Q filed 2025-11-06
2025-06-30$24.21M$20.66M-$41.45M-$49.94M
10-Q filed 2026-08-05
2025-03-31$20.25M$17.92M-$36.91M-$43.84M
10-Q filed 2026-05-06
2024-12-31$24.57M$22.09M-$27.66M-$37.51M
10-K filed 2026-03-02
Derived: the full year minus the first three quarters, not a figure this filer reported as a quarter.
Assembled from more than one filing; the filing above is only the newest of them.
2024-09-30$25.20M$22.75M-$17.55M-$23.67M
10-Q filed 2025-11-06
Assets
$252.59M
Equity
-$132.40M

Balance as of 2026-06-30.

Ten years

Fiscal year endRevenueOperating incomeNet incomeFree cash flow
2025-12-31$109.79M-$124.86M-$153.49M-$162.73M
2024-12-31$90.40M-$96.78M-$126.87M-$97.06M
2023-12-31$82.71M-$65.54M-$102.24M-$76.57M
2022-12-31$64.36M-$79.04M-$109.78M-$87.81M
2021-12-31$48.04M-$92.29M-$110.82M-$85.64M
2020-12-31$11.80M-$126.74M-$128.48M-$107.10M
2019-12-31$18,000-$109.48M-$105.15M-$71.34M
2018-12-31$1.13M-$77.18M-$75.66M-$37.89M
2017-12-31$8.16M-$19.95M-$20.00M-$9.84M
2016-12-31$17.53M$798,000-$1.94M$3.49M

Company filings

Insiders, politicians and funds

Insider trades, last 90 days

  • Schoenberg Mark

    Chief Medical Officer

    Sale$37,383

    Sep 9, 2:37 PM ET

  • Smith Jason Drew

    General Counsel

    Sale$64,618

    Sep 9, 2:35 PM ET

  • Schoenberg Mark

    Chief Medical Officer

    Sale$2,854,853

    Aug 24, 5:03 PM ET

  • Schoenberg Mark

    Chief Medical Officer

    Sale$400,000

    Jul 10, 2:17 PM ET

All insider trades for URGN

Politician trades, last 90 days

No politician trades filed in the last 90 days.

Funds

All funds

News

Stories that named URGN, and the market events around them.

Sign in to see this

Board

Recent signals

Signals open up here once a member has posted about URGN.

Signals are informational.

Posts · 0

No posts yet.

Be the first to say something about URGN.

nakagai

Signals on URGN come from a rule, not a model.

Nakagai’s scanner records a signal the moment a strategy’s rule matches on the bars. Members read those signals on their own desk, where an agent journals the tape and briefs them in plain English.

Members post on the URGN board

This page is not financial advice. Trade at your own judgment and risk. Read the terms that govern posting here.